

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4825345

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
THRESHOLD PHARMACEUTICALS, INC.	05/31/2017
RECEIVING PARTY DATA	
Name:	OBI PHARMA, INC.
Street Address:	7F., NO.369, SEC. 7, ZHONGXIAO E. RD., NANGANG DIST.
City:	TAIPEI CITY
State/Country:	TAIWAN
Postal Code:	115
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15752854
CORRESPONDENCE DATA	
Fax Number:	(202)672-5399
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(202)672-5300
Email:	ipdocketing@foley.com, nbalaban@foley.com
Correspondent Name:	FOLEY & LARDNER LLP
Address Line 1:	3000 K STREET N.W.
Address Line 2:	SUITE 600
Address Line 4:	WASHINGTON, D.C. 20007-5109
ATTORNEY DOCKET NUMBER:	117546-1103
NAME OF SUBMITTER:	NANI K. BALABAN
SIGNATURE:	/NANI K. BALABAN/ for Photon Rao
DATE SIGNED:	02/14/2018
Total Attachments: 3	
source=Assignment-OBI#page1.tif	
source=Assignment-OBI#page2.tif	
source=Assignment-OBI#page3.tif	

Exhibit A

PATENT AND PATENT APPLICATION
ASSIGNMENT

WHEREAS, Threshold Pharmaceuticals, Inc., a corporation duly incorporated under the laws of the State of Delaware, (hereinafter called "Assignor"), is the owner of the patents and patent applications set forth on Schedule I attached hereto (the "Patents"); and

WHEREAS, OBI, a corporation organized and existing under the laws of Taiwan, (hereinafter called "Assignee"), is desirous of acquiring all right, title and interest in and to the Patents.

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, Assignor does hereby sell, assign and transfer to Assignee, Assignor's entire right, title, and interest in and to the Patents, as well as any extensions, continuations, divisionals, and non-U.S. counterparts of, as well as, any patents and patent applications that claim priority to, the patents, as of the Effective Date; the same to be held and enjoyed by the Assignee for its own use and benefit, and for the use and benefit of its affiliated companies, successors, assigns or other legal representatives; together with all rights of recovery and of legal action for claims for past infringement and of interference or opposition proceedings of the Patents, with the right to sue for and collect the same for its own use and benefit, and for the use and benefit of its affiliated companies, successors, assigns, or other legal representatives, together with all rights of registration, maintenance, and protection thereof in any form, all rights to income, royalties, damages and payments now due or hereafter due or payable in respect thereto.

Assignor further agrees to use Commercially Reasonable Efforts to execute and deliver, from time to time, all further instruments of conveyance, assignment, and further assurances and perform all such other acts as may reasonably be required to transfer and assign all of the Assignor's right, title, and interest in and to the Patents.

Confidential
[29]

IN WITNESS WHEREOF, the Parties have caused the term sheet to be executed by their respectively duly authorized representative as set forth below.

OBI Pharma, Inc.

Threshold Pharmaceuticals, Inc.

By: *Kevin Poulos*
Name: Kevin Poulos
Title: Chief Commercial Officer
Date: 6/13/2017

By: *Mark Hopkins*
Name: Mark Hopkins, Ph.D., J.D.
Title: Vice President
Intellectual Property
and Assistant General Counsel
Date: May 31, 2017

Confidential
[30]

Schedule 1 to Exhibit A: ASSIGNED PATENT AND APPLICATION RIGHTS

Title	Patent Application No.
DNA Alkylating Agents	US 62/131,163 (expired)
Dimethylaminocarbonyl)phenoxy-4-nitrophenyl)-1-ethyl-N,N'-bis(ethylene)phosphoramidate	US 62/255,905 (expired)
Dimethylaminocarbonyl)phenoxy-4-nitrophenyl)-1-ethyl-N,N'-bis(ethylene)phosphoramidate	US 62/324,259 (expired)
Nitrobenzyl Derivatives of Anti-Cancer Agents	US 62/142,352 (expired)
DNA Alkylating Agents	PCT/US2016/021581
Dimethylaminocarbonyl)phenoxy-4-nitrophenyl)-1-ethyl-N,N'-bis(ethylene)phosphoramidate	PCT/US2016/062114
Nitrobenzyl Derivatives of Anti-Cancer Agents	PCT/US2016/025665

Confidential
[31]